Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Lisa Schots, Lynda Grine, Rani Soenen & Jo Lambert. (2022) Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey. Journal of Dermatological Treatment 33:3, pages 1473-1481.
Read now
Read now
Jean-Guillaume Letarouilly, Jean-Hugues Salmon & René-Marc Flipo. (2021) Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review. Expert Opinion on Drug Safety 20:9, pages 1087-1094.
Read now
Read now
Roberto Caporali, Yannick Allanore, Rieke Alten, Bernard Combe, Patrick Durez, Florenzo Iannone, Mike T. Nurmohamed, Sang Joon Lee, Taek Sang Kwon, Jean Soo Choi, Gahee Park & Dae Hyun Yoo. (2021) Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Review of Clinical Immunology 17:1, pages 85-100.
Read now
Read now
Masakazu Kondo & Hisakata Yamada. (2019) Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan. Modern Rheumatology 29:6, pages 928-935.
Read now
Read now
Articles from other publishers (7)
A. I. Zagrebneva, E. N. Simonova, T. V. Mezenova, N. B. Burmistrova, Yu. A. Gavrikova, Yu. A. Gavrikova, E. O. Morozova, Zh. M. Kodzeva & K. S. Sapogina. (2022) Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience. Modern Rheumatology Journal 16:6, pages 73-79.
Crossref
Crossref
Kastriot Kastrati, Daniel Aletaha, Gerd R Burmester, Eva Chwala, Christian Dejaco, Maxime Dougados, Iain B McInnes, Angelo Ravelli, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Desirée van der Heijde, Marieke J H Voshaar, Kevin Winthrop, Josef S Smolen & Andreas Kerschbaumer. (2022) A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 8:2, pages e002359.
Crossref
Crossref
Iciar Cañamares Orbis, Leticia Merino Meléndez, Irene Llorente Cubas, Juana Benedí González, Rosario García-Vicuña, Alberto Morell Baladrón, Isidoro González-Álvaro & Esther Ramírez Herraiz. (2020) Factores asociados a la persistencia a largo plazo de rituximab en artritis reumatoide en la práctica clínica: Estudio RITAR. Medicina Clínica 155:1, pages 1-8.
Crossref
Crossref
Iciar Cañamares Orbis, Leticia Merino Meléndez, Irene Llorente Cubas, Juana Benedí González, Rosario García-Vicuña, Alberto Morell Baladrón, Isidoro González-Álvaro & Esther Ramírez Herraiz. (2020) Factors associated with long-term persistence of rituximab in rheumatoid arthritis in clinical practice: RITAR Study. Medicina Clínica (English Edition) 155:1, pages 1-8.
Crossref
Crossref
E. S. Aronova, G. V. Lukina, S. I. Glukhova, G. I. Gridneva & A. V. Kudryavtseva. (2020) Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up. Terapevticheskii arkhiv 92:5, pages 39-45.
Crossref
Crossref
Zoltán Szekanecz. (2020) Biosimilars: To switch or not to switch – that is the question. Rheumatology 58:1, pages 1-3.
Crossref
Crossref
Piercarlo Sarzi-Puttini, Daniela Marotto, Roberto Caporali, Mauro Galeazzi, Fabiola Atzeni, Attila Hamar, Boglárka Soós & Zoltán Szekanecz. (2019) Biosimilars vs originators: Are they the same?. Autoimmunity Reviews 18:12, pages 102404.
Crossref
Crossref